查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985708

治疗诊断学市场：全球市场按产品类型、技术、应用领域和最终用户分類的预测－2026-2032年

Theranostics Market by Product Type, Technology, Application Area, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，治疗诊断学市场价值将达到 33.2 亿美元，到 2026 年将成长至 37.7 亿美元，复合年增长率为 14.16%，到 ​​2032 年将达到 84 亿美元。

主要市场统计数据
基准年 2025 33.2亿美元
预计年份：2026年 37.7亿美元
预测年份 2032 84亿美元
复合年增长率 (%) 14.16%

在快速发展的医疗环境中，我们利用诊断和治疗的整合来塑造个人化医疗的未来。

治疗诊断学代表着医疗保健领域的模式转移，它有望将诊断准确性和治疗效果整合起来，从而重新定义患者的治疗结果。诊断与标靶治疗的融合正在加速个人化医疗的进程，使临床医生能够根据分子谱、疾病进展标记和个体反应模式来优化治疗方法。随着影像学、生物标记和新型药物传递机制的融合发展，临床决策的基础正在被重构，其核心是高度特异性和数据驱动的路径。

技术和科学突破重新定义了临床环境中治疗诊断学解决方案的开发和整合。

在分子影像学突破、先进生物标记发现以及奈米技术平台蓬勃发展的推动下，治疗诊断学领域正经历着翻天覆地的变革。放射性药物偶联和标靶药物递送系统等技术创新，为以前所未有的精准度可视化和治疗病灶提供了前所未有的机会。随着次世代定序和机器学习演算法更深入地融入临床工作流程，诊断测试的预测能力正在改变治疗候选药物的选择和给药方式。

对美国关税政策对全球供应链和诊疗治疗诊断学趋势的影响进行全面评估。

美国在2025年实施的关税政策给全球治疗诊断学供应链带来了巨大压力，尤其是在放射性药物前驱物和专用诊断剂的采购方面。随着关键原料进口成本的上升，製造商被迫重新评估其筹资策略，越来越依赖区域合作伙伴并寻求垂直整合，以保护自身业务免受关税波动的影响。同时，研究机构也在评估替代试剂和同位素，以期在不影响分析性能的前提下，提供更具成本效益的解决方案。

对治疗诊断学产品（产品、技术、应用、最终用户）的每个层面进行详细的細項分析，以识别机会和挑战。

基于产品的检验细分錶明，诊断试剂和治疗试剂之间的二分法凸显了不同的创新路径。诊断试剂越来越注重能够检测微量残存疾病的高灵敏度分子成像探针，而治疗试剂则优先考虑能够同时监测治疗和药物递送的多功能结构。这种产品类型之间的相互作用形成了一个回馈迴路：诊断技术的进步会影响治疗标靶参数的调整，反之亦然。

揭示美洲、欧洲、中东和非洲以及亚太市场治疗诊断学解决方案扩张的区域特定驱动因素和部署模式。

治疗诊断学的区域发展趋势体现在应用率和创新生态系的差异。在美洲，分子影像和放射化学的基础设施已经成熟，健全的法规环境也促进了伴随诊断的早期应用。先进的支付模式和高度集中的学术研究中心正在推动整合诊断和治疗模式的快速普及，尤其是在肿瘤学领域。

本文重点介绍了透过颠覆性研发和市场定位，推动治疗诊断学系统内创新和策略合作的先锋组织。

治疗诊断学领域的主要企业因其整合跨学科研究能力和策略合作伙伴关係的能力而脱颖而出。一些开创性的生物技术和製药公司已建立内部放射化学和分子影像部门，以加速早期研发；与此同时，诊断领域的创新者正在建立合作开发伙伴关係，将伴随诊断整合到治疗产品线中。由此产生的专业知识交流正在催生超越医疗设备、诊断和製药领域传统界限的混合经营模式。

为产业领导者建立切实可行的策略路径，以利用治疗诊断学市场的技术进步和监管趋势。

产业领导者应采用协作式开发框架，整合诊断与治疗研发团队，打造无缝衔接的创新路径。从产品设计早期阶段就引入跨职能协作，可最大限度地减少研发重复，缩短核准时间，并协调监管沟通策略。透过采用一体化的计划管治结构，企业可以同步推进检测方法、影像通讯协定和候选治疗药物的研发进程。

阐明用于收集、检验和整合治疗诊断学市场分析中多维度资料的系统研究框架。

本分析的研究架构采用多层方法，以确保其稳健性和有效性。二手资讯来源包括同行评审的科学论文、监管文件和行业白皮书，这些资料提供了关于新兴技术、政策趋势和临床试验结果的基础性见解。这项桌上研究为识别治疗诊断学系统各个方面的关键趋势以及理解其竞争动态奠定了基础。

透过整合核心见解，这项工作重点阐述了诊断、治疗和新兴技术之间的协同作用将如何推动下一代个人化医疗的发展。

诊断准确性和治疗特异性的融合正在为个人化医疗开闢新道路，而治疗诊断学）正处于这一变革的前沿。核心研究表明，从先进的分子成像到基于奈米技术的递送系统，各项技术创新正在重新定义疾病检测和治疗的范式。监管流程向整合核准流程的转变以及支付方对基于结果的报销模式的关注，都为这些进展提供了支持。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章治疗诊断学市场：依产品类型划分

  • 诊断药物
  • 治疗药物

第九章治疗诊断学市场：依技术划分

  • 基于生物标记的治疗诊断学
  • 伴随诊断（CDx）
  • 基于基因疗法的治疗诊断学
  • 分子影像
  • 基于奈米科技的治疗诊断学
  • 基于放射性药物的治疗诊断学
  • 标靶药物递送

第十章治疗诊断学市场：依应用领域划分

  • 自体免疫疾病
  • 心血管疾病
  • 感染疾病
  • 发炎性疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤学
    • 乳癌
    • 肺癌
    • 神经内分泌肿瘤
    • 摄护腺癌
    • 甲状腺癌

第十一章治疗诊断学市场：依最终用户划分

  • 诊断影像中心
  • 医院及癌症治疗中心
  • 研究和学术机构
  • 专科诊所

第十二章治疗诊断学市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章治疗诊断学市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章治疗诊断学市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国治疗诊断学市场

第十六章：中国治疗诊断学市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics GmbH
  • Astellas Pharma Inc.
  • BAMF Health
  • Bayer AG
  • bioMerieux SA
  • Biosynth Ltd.
  • Cardinal Health, Inc.
  • Cerebral Therapeutics, Inc.
  • Clarity Pharmaceuticals
  • Curasight A/S
  • Curium Inc.
  • Evergreen Theragnostics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hermes Medical Solutions AB
  • Icon Group
  • Indi Molecular, Inc.
  • Integrated Clinical Oncology Network Pty Ltd.
  • Radiopharm Theranostics Limited
  • Ratio Therapeutics
  • Siemens Healthineers AG
  • SOFIE Co.
  • Telix Pharmaceuticals Limited
Product Code: MRR-61081604A0A5

The Theranostics Market was valued at USD 3.32 billion in 2025 and is projected to grow to USD 3.77 billion in 2026, with a CAGR of 14.16%, reaching USD 8.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.32 billion
Estimated Year [2026] USD 3.77 billion
Forecast Year [2032] USD 8.40 billion
CAGR (%) 14.16%

Harnessing the Convergence of Diagnostics and Therapeutics to Shape the Future of Personalized Healthcare in a Rapidly Evolving Landscape

Theranostics represents a paradigm shift in healthcare, uniting diagnostic precision and therapeutic efficacy into integrated solutions that promise to redefine patient outcomes. This fusion of diagnostics and targeted treatment is accelerating the movement toward personalized medicine, enabling clinicians to tailor interventions based on molecular profiles, disease progression markers, and individual response patterns. As the confluence of imaging, biomarkers, and novel drug delivery mechanisms gains momentum, the very fabric of clinical decision-making is being rewoven to center on highly specific, data-driven pathways.

In this rapidly evolving landscape, stakeholders across research, regulatory, and commercial domains are rallying around the potential of theranostic platforms to streamline drug development timelines, reduce adverse events, and enhance therapeutic indices. The integration of companion diagnostics with cutting-edge therapeutic agents is laying the groundwork for agile clinical trials and adaptive treatment protocols. Consequently, a growing ecosystem of interdisciplinary collaboration is emerging, fueled by converging expertise in molecular biology, radiology, nanotechnology, and bioinformatics.

Looking ahead, the maturation of theranostic frameworks will hinge on robust partnerships between innovators and healthcare providers, supported by regulatory clarity and reimbursement structures that acknowledge value-based outcomes. As this introduction sets the stage, subsequent sections will delve into transformative shifts, policy impacts, market segmentation, regional dynamics, and strategic imperatives that define the trajectory of theranostic advancements.

Unveiling the Technological and Scientific Breakthroughs Redefining How Theranostic Solutions Are Developed and Integrated Across Clinical Settings

The theranostic landscape is undergoing profound transformation driven by breakthroughs in molecular imaging, advanced biomarker discovery, and the proliferation of nanotechnology-based platforms. Technological innovations such as radiopharmaceutical conjugation and targeted drug delivery vehicles are unlocking unprecedented opportunities to visualize and treat disease loci with pinpoint accuracy. As next-generation sequencing and machine learning algorithms become more deeply entwined with clinical workflows, the predictive power of diagnostic assays is reshaping how therapeutic candidates are selected and administered.

Moreover, regulatory frameworks are progressively adapting to accommodate the dualistic nature of theranostic products. Regulatory agencies are engaging in more frequent stakeholder dialogues to streamline approval pathways, particularly for biomarker-based companion diagnostics. This shift is fostering a more integrated evaluation process that views diagnostics and therapeutics as a unified entity, thereby reducing time-to-market and fostering innovation incentives. At the same time, payers are exploring outcomes-based reimbursement models that reward precision medicine approaches, underscoring the economic rationale for integrated testing and treatment modalities.

From a commercialization standpoint, strategic alliances and in-licensing agreements are proliferating, as pharmaceutical and diagnostic companies seek to co-develop or cross-license complementary assets. These partnerships reflect an industry-wide recognition that no single entity can master the spectrum of capabilities-from advanced imaging instrumentation to molecular assay design and therapeutic formulation-required to deliver holistic theranostic solutions. Ultimately, these transformative shifts are not only redefining product roadmaps but also catalyzing a culture of translational science that bridges laboratory discoveries with bedside impact.

Assessing the Comprehensive Effects of United States Tariff Policies on Global Supply Chains and Research Dynamics in Theranostic Development

The introduction of United States tariffs in 2025 has exerted notable pressure on global theranostic supply chains, particularly in the procurement of radiopharmaceutical precursors and specialized diagnostic reagents. As import costs for key raw materials rise, manufacturers are being compelled to reassess sourcing strategies, often turning to regional partners or pursuing vertical integration to insulate operations from tariff-induced volatility. In parallel, research institutions are evaluating alternative reagents and isotopes that may offer more favorable cost structures without compromising analytical performance.

Amid these dynamics, some stakeholders are intensifying efforts to localize production of essential components, spurred by government incentives aimed at promoting domestic manufacturing capabilities. This localization trend is fostering new collaborations between biotech firms, contract manufacturing organizations, and academic centers to scale up radiochemistry facilities. Although such initiatives entail significant capital investment, the resulting supply chain resilience and reduced exposure to external tariff fluctuations are driving long-term strategic value.

Furthermore, the tariff landscape has precipitated a reevaluation of cross-border clinical trial networks. Sponsors are increasingly factoring in logistical complexities and potential delays when selecting clinical sites, particularly if the movement of diagnostic kits and radiopharmaceuticals is subject to heightened customs scrutiny. These considerations are leading to more geographically diversified trial designs, with a parallel emphasis on harmonizing regulatory requirements and ensuring standardized quality control across multiple jurisdictions. As a result, the cumulative impact of tariffs is reshaping both operational models and strategic frameworks within the theranostic ecosystem.

Mining In-Depth Segmentation Perspectives to Illuminate Opportunities and Challenges Across Theranostic Product, Technology, Application and End-User Tiers

In examining product-based segmentation, the dichotomy between diagnostic agents and therapeutic agents underscores divergent innovation trajectories. Diagnostic agents are increasingly focusing on high-sensitivity molecular imaging probes that can detect minimal residual disease, whereas therapeutic agents are prioritizing multifunctional constructs capable of simultaneous treatment monitoring and drug delivery. This interplay between product types is fostering a feedback loop in which diagnostic refinements inform therapeutic targeting parameters, and vice versa.

The technological segmentation reveals an expansive array of platforms shaping the field. Biomarker-based theranostics are benefiting from next-generation sequencing insights, companion diagnostics are gaining regulatory traction alongside targeted oncology therapies, and gene therapy-based approaches are integrating diagnostic triggers for conditional expression. Molecular imaging enhancements are improving spatial resolution, nanotechnology-based carriers are optimizing pharmacokinetics, radiopharmaceutical-based constructs are evolving with novel isotopes, and targeted drug delivery systems are achieving higher payload specificity. Each of these technological categories interacts synergistically, creating a mosaic of innovation where advances in one domain catalyze progress in another.

Application-area segmentation highlights that oncology remains the nucleus of theranostic deployment, with breast cancer, lung cancer, neuroendocrine tumors, prostate cancer, and thyroid cancer leading research efforts. Concurrently, autoimmune, cardiovascular, infectious, inflammatory, metabolic, and neurological disorders are receiving increasing therapeutic attention as diagnostic modalities become more versatile. Within end-user segmentation, diagnostic imaging centers, hospitals and cancer care centers, research and academic institutes, and specialty clinics are tailoring their service offerings to accommodate integrated test-and-treat protocols. These segments are forging distinct value propositions while leveraging shared technological innovations to address expanding clinical horizons.

Deciphering Unique Regional Drivers and Adoption Patterns Shaping Expansion of Theranostic Solutions Across Americas, EMEA and Asia-Pacific Markets

Regional dynamics in theranostics are characterized by differentiated adoption velocities and innovation ecosystems. In the Americas, established infrastructure for molecular imaging and radiochemistry is complemented by a robust regulatory environment that encourages early adoption of companion diagnostics. Progressive payer models and a high concentration of academic research centers are driving rapid incorporation of integrated test-and-treat paradigms, particularly in oncology.

Meanwhile, Europe, the Middle East & Africa present a heterogeneous landscape marked by pockets of excellence in precision oncology hubs, alongside regions where limited reimbursement frameworks and infrastructure gaps impede widespread deployment. Regulatory harmonization initiatives within the European Union are streamlining cross-border collaboration, while Middle Eastern and North African governments are increasingly investing in specialized facilities to attract clinical research initiatives. Africa's landscape is more nascent but holds promise as diagnostic capabilities expand through public-private partnerships.

In Asia-Pacific, a dynamic convergence of government-led healthcare modernization, a growing middle-income population, and entrepreneurial biotech ecosystems is fueling demand for theranostic solutions. Countries with established nuclear medicine programs are leading in radiopharmaceutical applications, while emerging markets are prioritizing more accessible biomarker-based diagnostics. Collaborative research networks across academic hospitals and industry consortia are laying the groundwork for broad-based adoption, positioning the region as a critical frontier for future growth.

Spotlighting Pioneering Organizations Driving Innovation and Strategic Collaborations in the Theranostics Ecosystem with Disruptive R&D and Market Positioning

Leading organizations in the theranostic domain are distinguished by their ability to integrate multidisciplinary research capabilities with strategic alliances. Several pioneering biotech and pharmaceutical companies are establishing in-house radiochemistry and molecular imaging divisions to accelerate early development, while diagnostic innovators are forging co-development partnerships to embed companion tests within therapeutic pipelines. The resulting cross-pollination of expertise is giving rise to hybrid business models that transcend traditional boundaries between device, diagnostic, and pharmaceutical segments.

Strategic collaborations between academic research institutes and commercial entities are further enriching the innovation landscape. By leveraging academic centers' deep knowledge of disease biology and pharmaceutical companies' development resources, these partnerships are expediting translational research and enabling seamless transition from bench to bedside. In parallel, contract research organizations and contract manufacturing specialists are scaling customized manufacturing processes for complex agents, ensuring regulatory compliance and quality control across global markets.

Investment activity is also influencing company positioning, as venture capital and corporate investors target next-generation platforms such as gene therapy-based theranostics and nanocarrier systems. These inflows are enabling smaller players to challenge incumbents by rapidly advancing niche applications or high-precision diagnostic tools. Collectively, these company-level initiatives underscore a competitive landscape where agility, technical depth, and collaborative acumen determine leadership in the theranostic ecosystem.

Crafting Pragmatic Strategic Pathways for Industry Leaders to Capitalize on Technological Advances and Regulatory Trends in the Theranostics Market

Industry leaders should embrace co-development frameworks that unite diagnostic and therapeutic R&D teams to foster seamless innovation pathways. Embedding cross-functional collaboration at the outset of product design will minimize development redundancies, shorten approval timelines, and align regulatory engagement strategies. By adopting integrated project governance structures, organizations can ensure synchronized advancement of assays, imaging protocols, and therapeutic candidates.

Furthermore, establishing regional manufacturing and distribution hubs can mitigate exposure to supply chain disruptions, including tariff-induced cost pressures. Investing in decentralized radiopharmaceutical production facilities and diversifying sourcing of critical reagents will enhance operational resilience. Concurrently, engaging proactively with reimbursement authorities to demonstrate clinical and economic value through real-world evidence generation will secure favorable coverage policies, unlocking broader patient access.

Finally, leveraging digital platforms and artificial intelligence tools to analyze longitudinal patient data will enable dynamic refinement of theranostic algorithms and personalized treatment pathways. Executives should prioritize partnerships with data analytics providers and invest in interoperable IT infrastructure to drive continuous performance optimization. These actionable steps will empower companies to navigate regulatory complexities, capitalize on technology advances, and cement leadership in the evolving theranostic arena.

Unraveling the Systematic Research Framework Employed to Gather, Validate, and Synthesize Multidimensional Data in Theranostic Market Analysis

The research framework underpinning this analysis employed a multi-tiered approach to ensure robustness and validity. Secondary data sources included peer-reviewed scientific publications, regulatory filings, and industry white papers, which provided foundational insights into emerging technologies, policy developments, and clinical trial outcomes. This desk research laid the groundwork for identifying key trends and mapping competitive dynamics across multiple dimensions of the theranostic ecosystem.

Primary research comprised in-depth interviews with subject-matter experts spanning academic researchers, clinical practitioners, diagnostic developers, and pharmaceutical executives. These interviews yielded qualitative perspectives on development challenges, regulatory nuances, and market adoption barriers. To enhance triangulation, primary responses were cross-verified with publicly available case studies and clinical trial registries, ensuring that interpretations aligned with empirical evidence and real-world outcomes.

Quantitative data analysis involved synthesizing operating metrics, scientific publication trends, and patent filings to gauge innovation trajectories. Data modeling techniques were applied to uncover correlations between technological maturation, regulatory shifts, and adoption rates. The combination of qualitative insights and quantitative validation facilitated a comprehensive view of the theranostic domain, enabling actionable conclusions and strategic recommendations that reflect both current realities and future potential.

Consolidating Core Insights to Highlight How Synergies Between Diagnostics Therapeutics and Emerging Technologies Will Drive the Next Era of Personalized Medicine

The convergence of diagnostic precision and therapeutic specificity is charting a new course for personalized healthcare, with theranostics at the forefront of this transformation. Core insights reveal that technological innovations-from molecular imaging enhancements to nanotechnology-based delivery systems-are redefining disease detection and treatment paradigms. These advancements are supported by regulatory momentum toward integrated approval pathways and payer interest in outcomes-driven reimbursement models.

Segmentation analysis emphasizes the interplay between product types, technology platforms, application areas, and end-user settings, highlighting where value creation opportunities intersect. Regional perspectives underscore the importance of localized infrastructure, regulatory harmonization, and targeted research initiatives in unlocking market potential. Company-level insights further demonstrate that collaborative R&D, agile manufacturing strategies, and strategic investments are critical factors shaping competitive advantage.

In sum, the next era of theranostics will be driven by synergies between diagnostics, therapeutics, and data analytics, fostering a healthcare ecosystem that delivers tailored interventions with improved efficacy and reduced toxicity. Stakeholders who strategically align across scientific, regulatory, and commercial dimensions will be best positioned to translate these synergies into sustainable growth and enhanced patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Theranostics Market, by Product Type

  • 8.1. Diagnostic Agents
  • 8.2. Therapeutic Agents

9. Theranostics Market, by Technology

  • 9.1. Biomarker-Based Theranostics
  • 9.2. Companion Diagnostics (CDx)
  • 9.3. Gene Therapy-Based Theranostics
  • 9.4. Molecular Imaging
  • 9.5. Nanotechnology-Based Theranostics
  • 9.6. Radiopharmaceutical-Based Theranostics
  • 9.7. Targeted Drug Delivery

10. Theranostics Market, by Application Area

  • 10.1. Autoimmune Disorders
  • 10.2. Cardiovascular Diseases
  • 10.3. Infectious Diseases
  • 10.4. Inflammatory Diseases
  • 10.5. Metabolic Disorders
  • 10.6. Neurological Disorders
  • 10.7. Oncology
    • 10.7.1. Breast Cancer
    • 10.7.2. Lung Cancer
    • 10.7.3. Neuroendocrine Tumors
    • 10.7.4. Prostate Cancer
    • 10.7.5. Thyroid Cancer

11. Theranostics Market, by End-User

  • 11.1. Diagnostic Imaging Centers
  • 11.2. Hospitals & Cancer Care Centers
  • 11.3. Research & Academic Institutes
  • 11.4. Specialty Clinics

12. Theranostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Theranostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Theranostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Theranostics Market

16. China Theranostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Actinium Pharmaceuticals, Inc.
  • 17.6. Ariceum Therapeutics GmbH
  • 17.7. Astellas Pharma Inc.
  • 17.8. BAMF Health
  • 17.9. Bayer AG
  • 17.10. bioMerieux SA
  • 17.11. Biosynth Ltd.
  • 17.12. Cardinal Health, Inc.
  • 17.13. Cerebral Therapeutics, Inc.
  • 17.14. Clarity Pharmaceuticals
  • 17.15. Curasight A/S
  • 17.16. Curium Inc.
  • 17.17. Evergreen Theragnostics, Inc.
  • 17.18. GE HealthCare Technologies, Inc.
  • 17.19. Hermes Medical Solutions AB
  • 17.20. Icon Group
  • 17.21. Indi Molecular, Inc.
  • 17.22. Integrated Clinical Oncology Network Pty Ltd.
  • 17.23. Radiopharm Theranostics Limited
  • 17.24. Ratio Therapeutics
  • 17.25. Siemens Healthineers AG
  • 17.26. SOFIE Co.
  • 17.27. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THERANOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THERANOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THERANOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKER-BASED THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKER-BASED THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKER-BASED THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERANOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS (CDX), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THERANOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS (CDX), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THERANOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS (CDX), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THERANOSTICS MARKET SIZE, BY GENE THERAPY-BASED THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THERANOSTICS MARKET SIZE, BY GENE THERAPY-BASED THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THERANOSTICS MARKET SIZE, BY GENE THERAPY-BASED THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THERANOSTICS MARKET SIZE, BY NANOTECHNOLOGY-BASED THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THERANOSTICS MARKET SIZE, BY NANOTECHNOLOGY-BASED THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THERANOSTICS MARKET SIZE, BY NANOTECHNOLOGY-BASED THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THERANOSTICS MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THERANOSTICS MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THERANOSTICS MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THERANOSTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THERANOSTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THERANOSTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THERANOSTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THERANOSTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THERANOSTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THERANOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THERANOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THERANOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THERANOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THERANOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THERANOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THERANOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THERANOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THERANOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THERANOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THERANOSTICS MARKET SIZE, BY THYROID CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THERANOSTICS MARKET SIZE, BY THYROID CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS & CANCER CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS & CANCER CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS & CANCER CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THERANOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THERANOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THERANOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS THERANOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL THERANOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. GCC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GCC THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 142. GCC THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. G7 THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. G7 THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 160. G7 THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. NATO THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. NATO THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 166. NATO THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA THERANOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)